《盈利預喜》藥明生物(02269.HK)料中期純利按年增58%以上
藥明生物(02269.HK)發盈喜,預期截至今年6月底止中期純利按年增長58%以上,主因集團迅速開展有效的業務連續性計劃,以儘量降低新冠肺炎疫情對其業務及運營帶來的影響;集團研發管線引入更多客戶項目,支持全球客戶加快疫情相關潛在療法的開發及生產;集團現有產能利用率的提升,部分被新生產基地產能爬坡及隨著集團業務增長而增加的行政開支所抵銷;及投資、外匯、往年退稅收益及錄得其他營業外收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.